CARD has created a low-cost, visually-read rapid diagnostic technology platform delivering 1pg/ml sensitivity, a massive improvement on previous levels, along with device formats and assay operation principles which ensure simple, accurate and effective performance with clinical samples. The project has created a development pathway that will produce high-sensitivity assays for all protein targets.
As a pioneer in rapid point-of-care diagnosis, Mologic is driven by a commitment to continually improving performance and sensitivity, and pushing the technology into new applications and markets around the world.
“The vision for CARD is superior diagnostics that are accessible to everyone who needs them, while performing at the highest levels possible.”
Paul Davis, Chief Scientific Officer, Mologic